Microbiota, Immune Subversion, and Chronic Inflammation by Carolyn D. Kramer & Caroline Attardo Genco
March 2017 | Volume 8 | Article 2551
Mini Review
published: 13 March 2017
doi: 10.3389/fimmu.2017.00255
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Kuldeep Dhama, 
Indian Veterinary Research 
Institute, India
Reviewed by: 
Hafiz M. N. Iqbal, 
Monterrey Institute of Technology 
and Higher Education, Mexico  
Sunil Joshi, 
Old Dominion University, USA  
Ashok Munjal, 
Barkatullah University, India
*Correspondence:
Caroline Attardo Genco 
caroline.genco@tufts.edu
Specialty section: 
This article was submitted to 
Microbial Immunology, 
a section of the journal 
Frontiers in Immunology
Received: 15 December 2016
Accepted: 21 February 2017
Published: 13 March 2017
Citation: 
Kramer CD and Genco CA (2017) 
Microbiota, Immune Subversion, 
and Chronic Inflammation. 
Front. Immunol. 8:255. 
doi: 10.3389/fimmu.2017.00255
Microbiota, immune Subversion,
and Chronic inflammation
  
Carolyn D. Kramer and Caroline Attardo Genco*
Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, MA, USA
Several host-adapted pathogens and commensals have evolved mechanisms to 
evade the host innate immune system inducing a state of low-grade inflammation. 
Epidemiological studies have also documented the association of a subset of these 
microorganisms with chronic inflammatory disorders. In this review, we summarize 
recent studies demonstrating the role of the microbiota in chronic inflammatory 
diseases and discuss how specific microorganisms subvert or inhibit protective 
signaling normally induced by toll-like receptors (TLRs). We highlight our work 
on the oral pathogen Porphyromonas gingivalis and discuss the role of microbial 
modulation of lipid A structures in evasion of TLR4 signaling and resulting systemic 
immunopathology associated with atherosclerosis. P. gingivalis intrinsically expresses 
underacylated lipid A moieties and can modify the phosphorylation of lipid A, leading 
to altered TLR4 signaling. Using P. gingivalis mutant strains expressing distinct lipid 
A moieties, we demonstrated that expression of antagonist lipid A was associated 
with P. gingivalis-mediated systemic inflammation and immunopathology, whereas 
strains expressing agonist lipid A exhibited modest systemic inflammation. Likewise, 
mice deficient in TLR4 were more susceptible to vascular inflammation after oral 
infection with P. gingivalis wild-type strain compared to mice possessing functional 
TLR4. Collectively, our studies support a role for P. gingivalis-mediated dysregulation 
of innate and adaptive responses resulting in immunopathology and systemic inflam-
mation. We propose that anti-TLR4 interventions must be designed with caution, 
given the balance between the protective and destructive roles of TLR signaling in 
response to microbiota and associated immunopathologies.
Keywords: microbiota, inflammation, toll-like receptors, innate immunity, immune subversion, immune 
dysregulation, atherosclerosis
inTRODUCTiOn
Many inflammatory conditions and immunological disorders have been recently linked to the 
microbiota (1). Studies in humans have documented that both shifts in the microbiota (dysbiosis) 
and specific microorganisms are associated with these immunological disorders (2–4). A number of 
epidemiological studies have reported phylogenetic differences in the presence and relative abun-
dance of specific microbial communities between subjects with a particular disease and “healthy” 
individuals (5–7). While overall shifts in biodiversity within (alpha diversity) or among (beta 
diversity) subject samples are often reported, more recent work has considered functional diversity 
elucidated by metagenomic analyses (8, 9). The most well-studied microbial dysbiosis is that of the 
gut microbiota, which is associated with inflammatory bowel diseases (IBD) and colorectal cancer 
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(7, 9–11). Dysbiosis of the oral microbiota has been associated with 
oral squamous cell carcinoma (OSCC), and dysbiosis of the lung 
microbiota has been associated with cystic fibrosis (CF) (12–15). 
However, gut microbiota dysbiosis has also been associated with 
non-intestinal diseases including obesity, type 1 diabetes (T1D), 
rheumatoid arthritis (RA), and atherosclerosis (16, 17). Likewise, 
dysbiosis of the oral microbiota has been associated with diseases 
occurring outside of the oral cavity, such as lung and pancreatic 
cancers as well as atherosclerosis and RA (18–21).
In addition to dysbiosis, the presence of specific microor-
ganisms has also been associated with cancer, atherosclerosis, 
autoimmune disorders, and RA (22–40). Indeed, much of the 
experimental evidence aimed at defining mechanistic links 
between the microbiota and systemic inflammatory conditions 
has focused on metabolic and immunological pathways induced 
by specific microorganisms. In this review, we summarize recent 
studies aimed at defining immunological mechanisms that link 
specific microorganisms to low-grade chronic inflammation and 
immunopathology.
MiCROBiOTA AnD CHROniC 
inFLAMMATORY DiSeASeS
In June 2012, the Human Microbiome Project Consortium 
(HMP) reported on the “healthy” microbiome at 15–18 anatomic 
sites and provided a framework for future studies on defining the 
association of the microbiome with disease states. In the few years 
since the healthy baseline was established, a number of reports 
have defined altered microbiota that may contribute to disease. 
A common finding among studies investigating dysbiosis of 
the microbiota was a decrease in alpha diversity in diseased vs. 
healthy states (41–48). Many studies have also demonstrated that 
changes in the microbiome correlate with the pathogenesis of 
various systemic inflammatory diseases (17, 18, 47, 48). As might 
be expected, changes in the microbiota specific to a particular 
anatomic location have been associated with inflammatory dis-
eases of that area as well as distant tissues or organs.
Association of Microbiota with Local 
inflammation
Several studies have linked IBD with dysbiosis of the gut micro-
biota characterized by decreases in Bifidobacterium, Clostridium, 
and Faecalibacterium prausnitzii and increases in Ruminococcus 
gnavus and adherent-invasive Escherichia coli (46, 49–51). In sub-
jects with IBD, there was also a decrease in the genus Roseburia; 
interestingly, this decrease was observed in healthy subjects with 
a high genetic risk for IBD (52–55). Not only was dysbiosis of the 
gut microbiota associated with IBD but distinct shifts in the gut 
microbiota and a decrease in alpha diversity were also shown to 
distinguish ileal vs. colonic Crohn’s disease (55). Significant phy-
logenetic differences were found between patients who respond 
to treatment for ulcerative colitis vs. those who do not respond 
to treatment (53).
Many cancers have now been linked to dysbiosis of the local 
microbiota. The gut microbiome of colorectal cancer patients 
includes significantly higher populations of Enterococcus faecalis, 
Streptococcus bovis, and Fusobacterium than the microbiota of 
healthy controls (56). The oral cancer OSCC is associated with 
a shift in the oral microbiome. Streptococcus species dominate 
the salivary microbiota within OSCC tumor sites compared to 
non-tumor sites within the same individual (57). There also is sig-
nificant enrichment of Actinobacteria, Bacteroidetes, Firmicutes, 
Proteobacteria, Porphyromonas, and Treponema in the uterine 
microbiota of individuals with endometrial cancer (58).
Association of Microbiota with Systemic 
inflammation at Sites Distant from 
infection
Changes in the gut microflora have also been associated with 
metabolic and inflammatory conditions distant from infection 
including obesity, diabetes, and autoimmune diseases. Studies 
have reported that the relative proportion of Actinobacteria and 
Bacteroidetes was increased and decreased, respectively, in the 
gut microbiota of obese individuals compared to lean individuals 
(43, 59). An increased abundance of Bacteroidetes and Bacteroides 
and a decreased abundance of Firmicutes and Bifidobacterium 
and Prevotella were also reported to distinguish the intestinal 
microbiome of children with T1D from that of age-matched 
healthy controls (45, 60–62).
An increased abundance of Prevotella and a decreased abun-
dance of Bacteroides were reported in stool samples from subjects 
with new-onset RA compared to healthy controls (63). A separate 
study characterized an RA-associated fecal microbiome as one in 
which Actinobacteria and Collinsella and Eggerthella were con-
sistently expanded while Faecalibacterium was notably decreased 
compared to healthy controls (47). A recent study examined both 
the gut and oral microbiota of subjects with RA and reported 
increased levels of Lactobacillus salivarius and decreased levels of 
Haemophilus spp. compared to healthy controls in both sites (64). 
Shifts in the oral microbiome have been reported in subjects with 
RA, including lower levels of Corynebacterium and Streptococcus 
compared to healthy controls (18). Subjects with new-onset RA 
also have shifts in the oral microbiota with increases in Prevotella 
and Leptotrichia; these organisms were absent in the oral micro-
biota of healthy controls (18). Bronchoalveolar lavage fluid from 
subjects with early RA revealed dysbiosis of the lung microbiome 
that was attributed to a significant decrease in Actynomyces, 
Burkholderia, Porphyromonas, Prevotella, and Treponema com-
pared to healthy controls (48).
Some cancers have been associated with oral microbiota 
changes at sites distant from the primary tumor. In saliva samples 
from subjects with lung cancer, Capnocytophaga, Selenomonas, 
and Veillonella were more abundant and Neisseria was less 
abundant compared to healthy controls (19). The presence of 
the oral pathogens P. gingivalis and Aggregatibacter actinomyce-
temcomitans in oral wash samples were associated with a higher 
risk of pancreatic cancer, while presence of Fusobacteria and 
Leptotrichia in oral wash samples was associated with a lower risk 
of pancreatic cancer risk (65).
Shifts in the gut and oral microbiota have also been associated 
with symptomatic atherosclerosis patients. The gut microbiota of 
subjects with atherosclerosis had increased levels of Desulfovibrio, 
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Enterobacter, Megasphaera, and Oscillibacter and less Bacteroides, 
Faecalibacterium, and Prevotella compared to asymptomatic 
subjects (66). Subjects with symptomatic atherosclerosis have 
elevated levels of several genera of bacteria in the oral cavity, 
including Anaeroglobus and Porphyromonas (20).
innATe iMMUne MeCHAniSMS LinKinG 
SPeCiFiC MiCROORGAniSMS TO 
CHROniC inFLAMMATiOn AnD 
iMMUnOPATHOLOGY
A number of studies have examined the ability of pathogens to 
induce systemic inflammation and immunopathology at sites 
distant from infection. Well-defined animal models of RA, 
cancer, and atherosclerosis have been utilized to demonstrate a 
link between infection with specific pathogens and acceleration 
of disease (67–75). Many of these studies have focused on the role 
of the innate immune system and in particular toll-like receptors 
(TLRs) in microbial-induced immunopathology and disease (70, 
73, 76–82).
Toll-like receptors detect conserved microbial products 
and play a central role in the activation of innate and adaptive 
immune pathways (83, 84). TLR2 and TLR4 are two of the most 
well-characterized TLRs that respond to microbial membrane 
components. TLR2 is a cell-surface receptor that recognizes path-
ogen-associated molecular patterns (PAMPs) that are typically 
associated with both Gram-positive and Gram-negative bacteria, 
such as lipoproteins, lipoteichoic acid, peptidoglycan, zymosan, 
and porins (85–89). TLR4 is a cell-surface receptor that recognizes 
lipopolysaccharide (LPS) from Gram-negative bacteria (90–92). 
Signal transduction following recognition of LPS by the TLR4 
complex (CD14–TLR4–MD2) is an essential component of host 
immunity to Gram-negative bacterial infection (93). TLR4 signals 
through MyD88- and TRIF-dependent pathways to promote 
proinflammatory cytokine production and type I IFN (IFNβ) 
responses, respectively (94, 95). In addition to PAMPs, various 
endogenous “danger” molecules released from damaged host cells 
activate TLRs; these molecules are known as danger-associated 
molecular patterns and include heat-shock proteins, hyaluronic 
acid, and oxidized low-density lipoprotein (96).
Engagement of TLR signaling triggers an inflammatory 
response that is primarily aimed at eliminating the invading 
organisms, initiating repair to damaged tissues, and initiating 
the adaptive immune response (83, 84, 86, 97–99). When well 
controlled, this beneficial inflammatory response manages a 
delicate balance between the clearance of pathogens and dam-
age to the host through feedback loops and negative regulation, 
resolving once the stimulus has been removed (Figure  1A) 
(100–102). Clearance of pathogens is orchestrated through a 
combination of antimicrobial peptides, inflammatory media-
tors, phagocytosis, autophagy, and inflammasome activation 
(Figure 1A) (97, 103, 104). Chronic inflammation occurs when 
there is a breakdown in the regulation of these processes, which 
disrupts host cells locally and systemically, and it is increas-
ingly associated with chronic conditions such as autoimmune 
diseases, cancer, IBD, arthritis, and atherosclerosis (105–107). 
We recently demonstrated that differential TLR signaling by 
variant P. gingivalis lipid A moieties was associated with the pro-
duction of proinflammatory mediators and bacterial survival in 
macrophages (Figure 1B) (108).
A number of studies have examined the role of TLR signaling 
in microbial-induced chronic inflammation and immunopathol-
ogy (70, 73, 76, 82). Mycobacterium tuberculosis and commensal 
gut microbiota have been shown to induce autoimmune arthritis 
through TLR signaling (73, 76). E. coli has been shown to increase 
non-small cell lung cancer metastasis in a TLR4-dependent 
manner (82). Chlamydia pneumoniae accelerates atherosclerosis 
through a TLR/MyD88-dependent mechanism (70). Our work 
has focused on defining the role of TLR2 and TLR4 signaling 
in P. gingivalis-mediated inflammatory atherosclerosis using a 
well-defined hyperlipidemic mouse model (ApoE−/−) (77–81). 
Numerous studies have documented a role for TLR signaling in 
lipid-induced atherosclerosis progression (110–113). Oxidized 
LDL particles are recruited to the atheroma and trigger TLR sign-
aling in macrophages and endothelial cells. This results in foam 
cell formation and the production of proinflammatory cytokines 
and other proinflammatory mediators, such as IL-1, TNFα, 
and macrophage colony-stimulating factor, which perpetuate 
inflammation within the vasculature (109, 114, 115). It has been 
postulated that the association between microbial infection and 
atherosclerosis involves common mechanisms of signaling via 
TLR2 and TLR4. Some investigators have proposed that TLR 
signaling induced by multiple pathogens and endogenous ligands 
may explain the link to atherosclerosis and that therapeutic TLR 
antagonism could prove beneficial in the treatment of chronic 
atherosclerosis (13, 14, 116–118). However, our work revealed 
that P. gingivalis-mediated TLR4 signaling protects from athero-
sclerosis, suggesting that effects are pathogen specific.
We established that oral infection with P. gingivalis is associated 
with lipid accumulation and macrophage infiltration in the aortic 
sinus and innominate artery of ApoE−/− mice (69, 71). P. gingivalis 
oral infection induced the expression of inflammatory mediators 
and proinflammatory cytokines such IFN-γ, IL-1β, interleukin-6 
(IL-6), and TNFα in the atherosclerotic lesions of ApoE−/− mice, 
which was significantly reduced in the atherosclerotic lesions 
of P. gingivalis-infected ApoE−/−TLR2−/− mice (77–79, 81). 
In contrast to the effect of TLR2-deficiency on P. gingivalis-
induced atherosclerosis, we demonstrate that TLR4-deficiency 
leads to increased disease severity, indicating a protective role 
for TLR4 signaling in P. gingivalis-induced atherosclerosis (80). 
P. gingivalis-infected TLR4-deficient mice had increased vascular 
inflammation characterized by enhanced lesion progression 
and increased macrophage accumulation compared to infected 
TLR4-sufficient mice (80). In contrast to what was observed with 
P. gingivalis, other reports have documented that TLR4-deficient 
mice infected intranasally with C. pneumoniae had diminished 
vascular inflammation compared to infected TLR4+/+ mice. These 
results suggest that the role of TLR4 signaling in atherosclerosis 
is pathogen specific.
Porphyromonas gingivalis-infected TLR4-deficient mice also 
had increased CD4/CD8 T cells, decreased regulatory T cell infil-
tration, and impaired Th1 immunity, implicating modulation of 
the adaptive immune response (80). Our results suggest that this 
FiGURe 1 | Continued  
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TABLe 1 | Gram-negative bacteria that express divergent lipid A structures.
Bacterial strain Acylation/phosphorylation Toll-like receptor 4 
activation
Outcomes Reference
Helicobacter pylori Mono-phosphorylated, tetra-acylated Weak agonist Bacterial survival (119, 127)
Pseudomonas aeruginosa Hepta-acylated Strong agonist Severe cystic fibrosis (CF), neutrophil survival (120)
Penta-acylated Weak agonist Decreased IL-8, CF
Bacteroides thetaiotaomicron Under-phosphorylated, penta-acylated Weak agonist Bacterial survival (121, 128)
Porphyromonas gingivalis Di-phosphorylated, penta-acylated Agonist Modest inflammation, decreased atherosclerosis (108, 122)
Mono-phosphorylated, tetra-acetylated Antagonist Systemic inflammation, increased atherosclerosis
S. flexneri Tri- or tetra-acylated Weak agonist Low cytokine production, inflammasome inhibition (123)
Neisseria meningitidis Penta-acylated Non-activating Low NFkB activation (124)
Yersinia pestis Hexa-acylated Strong agonist Bacterial clearance, no systemic disease (125, 129, 130)
Tetra-acylated (37°C) Weak agonist Systemic disease
Francisella tularensis Mono-phosphorylated, tetra-acetylated Weak agonist Decreased TNFα, bacterial survival (126, 131, 132)
The role of toll-like receptor (TLR) signaling in chronic inflammation. (A) During a normal inflammatory response, activation of TLR signaling results in an 
increase in proinflammatory mediators and antimicrobial peptides, activation of the inflammasome, and clearance of the pathogen (97, 103, 104). Eradication of the 
stimulus results in resolution of inflammation (100–102). Some bacteria inhibit one or more of these responses, preventing the resolution of inflammation. 
(B) Porphyromonas gingivalis activation of TLR2 results in decreased production of proinflammatory cytokines such as IL-12 and IFN-γ, impairing bacterial clearance 
(109). P. gingivalis expressing a TLR4 antagonist lipid A moiety produces low levels of IL-1β and prevents activation of the non-canonical inflammasome, which also 
impairs bacterial clearance (108). In contrast, P. gingivalis expressing a TLR4 agonist lipid A moiety produces high levels of IL-1β and activates the inflammasome (108).
FiGURe 1 | Continued
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protective role of TLR4 signaling may be orchestrated by dendritic 
cell (DC) IL-10 and IL-12 as well as by the induction of regulatory 
T cells (80). Collectively, our studies indicate that P. gingivalis-
mediated dysregulation of innate and adaptive responses results 
in systemic inflammation and immunopathology.
innATe iMMUne SUBveRSiOn
A common theme that has recently emerged is that pathogens 
that are associated with chronic low-grade inflammation have 
developed mechanisms of immune subversion that either alter 
or inhibit protective signaling normally induced by TLRs. Lipid 
A, the biologically active moiety of LPS, can be expressed in 
variant forms by many human pathogens, allowing for evasion 
of the host innate immune system and establishment of a chronic 
infection (119–126). Table 1 summarizes the impact of impaired 
TLR4 signaling as a result of divergent lipid A of several immune 
subversive Gram-negative bacteria. Strikingly, several of these 
host-adapted Gram-negative bacteria that express immune-
evasive lipid A are associated with increased risk of autoimmune 
disease, atherosclerosis, and cancer. Although Helicobacter pylori 
expresses a hexa-acylated species of lipid A, its predominant 
lipid A species is mono-phosphorylated and tetra-acylated; this 
combination of underphosphorylation and underacylation of 
lipid A likely explains the low endotoxic and biological activities 
of H. pylori LPS (119).
SenGupta et al. (120) reported that structural lipid A variants of 
Pseudomonas aeruginosa correlate with severity and progression 
of CF. Specifically, hepta-acylated lipid A is uniquely associated 
with severe late stage CF, and this variant acts as a strong TLR4 
agonist, resulting in neutrophil survival and substantial produc-
tion of IL-8 (120). Penta-acylated lipid A is found in patients with 
early stage or less severe (CF), accompanied by lower levels of 
IL-8 compared to those with severe late stage CF (120).
Bacteroides thetaiotaomicron expresses a penta-acylated 
4′-dephosphorylated lipid A structure and exhibits resistance to 
various inflammation-associated CAMPs (121, 128). Using wild-
type and lpxF mutant strains of B. thetaiotaomicron, Cullen et al. 
(128) demonstrated that CAMP resistance is LpxF-dependent 
but is also inflammation-dependent as lpxF deletion mutants 
were outcompeted by wild-type bacteria in germ-free mice 
only in the presence of inflammatory Citrobacter rodentium 
infection. These authors noted that LpxF orthologs have been 
identified in all sequenced human-associated Bacteroidetes. In 
addition to B. thetaiotaomicron, four other human-associated 
Bacteroides (Bacteroides fragilis, Bacteroides vulgatus, Prevotella 
salivae, and P. gingivalis) produce an under-phosphorylated lipid 
A structure (128).
Several Gram-negative bacteria that express immune-evasive 
lipid A species are associated with an increased risk of atheroscle-
rosis (133, 134), but the oral pathogen P. gingivalis is a striking 
example of how lipid A variants allow a bacterium to evade TLR4 
and promote chronic inflammation through dysregulation of 
both innate and adaptive immune responses (71, 78–80, 135).
In response to environmental conditions, P. gingivalis 
expresses a variety of lipid A species that are described as TLR4 
agonist, antagonist, or non-stimulating depending on their 
phosphorylation and acylation states and the resulting immu-
nostimulatory activity (122, 136–140). The underacylated lipid 
A moieties are poorly recognized by TLR4, and the antagonist 
lipid A species inhibits activation of TLR4 by agonist lipid 
A species from P. gingivalis or other Gram-negative organisms 
(122, 139, 141, 142). We recently examined the role of these 
P. gingivalis lipid A variants in vitro and in a mouse model of vascular 
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inflammation. We demonstrated that the antagonist lipid A species 
enhanced bacterial survival in macrophages through inhibition 
of non-canonical inflammasome activation and decreased pro-
duction of proinflammatory mediators such as IL-1β (Figure 1B) 
(108). In contrast, the agonist lipid A species was associated with 
decreased bacterial survival in macrophages and high levels of 
IL-1β (Figure 1B) (108). ApoE−/− mice orally infected with the 
P. gingivalis wild-type or antagonist strains had progressive vas-
cular inflammation characterized by enhanced lesion progression 
and increased macrophage accumulation compared to either 
sham-infected ApoE−/− mice or ApoE−/− mice that were orally 
infected with the P. gingivalis agonist strain. These studies indicate 
that distinct lipid A moieties allow P. gingivalis to evade the host 
innate immune response resulting in vascular inflammation. In 
addition to facilitating bacterial survival, it is possible that distinct 
lipid A moieties dysregulate host adaptive immune responses 
through manipulation of DC activation and downstream T cell 
polarization leading to systemic inflammatory pathologies.
DYSReGULATiOn OF ADAPTive 
iMMUniTY AnD CHROniC 
inFLAMMATiOn
Dysregulation of host immunity has been proposed to contribute 
to chronic inflammation observed in systemic inflammatory dis-
eases and typically involves modulation of DC responses, critical 
antigen-presenting cells that link innate and adaptive immunity. 
DCs play a key role in immune-modulatory functions and are 
often targeted by pathogens, resulting in altered T cell-mediated 
adaptive responses, immune dysregulation, and immunopathol-
ogy. Immature and highly phagocytic DCs reside in the tissues 
and detect pathogens through PRRs including DC-SIGN, TLR2, 
TLR4, NOD2, and the mannose receptor (143). PRR ligation and 
pathogen phagocytosis initiate DC maturation, which is charac-
terized by a decrease in phagocytic capability and an upregula-
tion of co-stimulatory molecules that are involved in activating 
T cells. The type of T cell response is dictated by which PRR is 
activated and, consequently, which cytokines are produced (143). 
The induction of a CD4 T cell response is largely determined by 
pathogen detection by DCs that present antigens to naïve T cells 
to initiate an adaptive response. DCs can also be activated to 
efficiently cross-present extracellular antigens on MHC-I, leading 
to activation of CD8 T cells (144, 145).
Lipopolysaccharide isolated from the Gram-negative pathogens 
E. coli and Salmonella enterica serotype Typhimurium potently 
stimulate TLR4 on DCs leading to maturation and expression of 
proinflammatory cytokines that drive a Th1 response (143). The 
expression of immune-evasive LPS by host-adapted bacteria such 
as P. gingivalis may result in different DC responses leading to 
altered T cell responses. However, the impact of immune-evasive 
LPS on systemic immunopathology has not been explored. We 
postulate that altered DC activation by P. gingivalis lipid A mutant 
strains will result in dysregulation of adaptive immunity that leads 
to enhanced development and progression of atherosclerosis. 
Current studies are underway to define how modification of lipid 
A alters DC maturation and functional responses.
iMPLiCATiOnS FOR FUTURe THeRAPieS
Studies demonstrating a protective role for TLR deficiency 
in inflammation have prompted many to pursue therapeutic 
TLR antagonism for combating systemic inflammatory and 
autoimmune diseases. These TLR antagonists include structural 
analogs of agonists, anti-TLR antibodies, and small molecule 
antagonists. One example of a structural analog is eritoran, 
a TLR4 antagonist that inhibits LPS-induced inflammation 
and improves survival in a mouse model of sepsis (146). The 
small molecule inhibitor TAK-242 inhibits TLR4 signaling by 
binding selectively to TLR4 and disrupting interaction with its 
adaptor molecules (147). Wang et  al. (148) demonstrated that 
TAK-242 diminished the accumulation of DCs, lymphocytes, 
macrophages, and neutrophils and enhanced production of IL-6, 
IL-8, and TNF-α in a mouse model of cigarette smoke-induced 
pulmonary inflammation. It has been suggested that therapy with 
eritoran or TAK-242 may be most efficacious against bacteria 
expressing hexa-acylated lipid A structures, which act as strong 
TLR4 agonists and elicit local inflammation but typically result 
in bacterial clearance and no systemic disease (149). In contrast, 
bacteria that do not produce hexa-acylated lipid A elicit little or 
no TLR4-mediated local inflammation, which permits bacterial 
survival and dissemination and contributes to the development 
and progression of systemic diseases. Anti-TLR4 therapy has 
been suggested as a prophylactic for necrotizing enterocolitis 
(NEC), but a recent study demonstrated that secretions from the 
probiotic Bifidobacterium longum subspecies infantis, often used 
to treat NEC, attenuate IL-1β-induced IL-6 in a TLR4-dependent 
manner in a human fetal small intestinal epithelial cell line (H4 
cells) and primary NEC enterocytes (150). Despite the promis-
ing results of using TLR4 antagonists to prevent inflammation 
in mice, our results and others suggest that the role of TLR4 
signaling in the pathogenesis of chronic inflammatory diseases 
is pathogen specific and that TLR4 antagonism could encourage 
systemic inflammation and dissemination of certain pathogens 
resulting in unintended outcomes (80, 108, 150). In addition, the 
presence of comorbid conditions and the bacterial characteristics 
of both local and distant microbiota create a complex environ-
ment in which chronic disease develops and progresses. For these 
reasons, we advocate caution in the development and testing of 
TLR4 antagonists for the treatment of chronic inflammatory 
diseases induced by the microbiota.
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